Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 7% – What’s Next?

by · The Markets Daily

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) were down 7% on Monday . The stock traded as low as $17.27 and last traded at $17.31. Approximately 241,679 shares changed hands during trading, a decline of 79% from the average daily volume of 1,143,480 shares. The stock had previously closed at $18.61.

Analysts Set New Price Targets

A number of research firms recently weighed in on CAPR. Oppenheimer reaffirmed an “outperform” rating and set a $15.00 price objective on shares of Capricor Therapeutics in a research report on Monday, September 23rd. HC Wainwright reissued a “buy” rating and set a $77.00 target price on shares of Capricor Therapeutics in a research note on Thursday. Maxim Group lifted their target price on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Piper Sandler began coverage on shares of Capricor Therapeutics in a research report on Monday, October 21st. They set an “overweight” rating and a $35.00 price target on the stock. Finally, Cantor Fitzgerald upped their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Capricor Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Get Our Latest Stock Report on Capricor Therapeutics

Capricor Therapeutics Price Performance

The business’s 50 day moving average is $15.21 and its 200-day moving average is $8.50. The company has a market cap of $864.53 million, a PE ratio of -17.56 and a beta of 4.00.

Insider Activity at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the business’s stock in a transaction on Friday, September 20th. The stock was bought at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the transaction, the insider now owns 7,090,351 shares in the company, valued at $38,004,281.36. This represents a 65.21 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 12.00% of the stock is owned by insiders.

Institutional Trading of Capricor Therapeutics

Large investors have recently modified their holdings of the business. Barclays PLC raised its stake in Capricor Therapeutics by 106.6% during the third quarter. Barclays PLC now owns 36,296 shares of the biotechnology company’s stock worth $552,000 after purchasing an additional 18,724 shares during the period. Sphera Funds Management LTD. purchased a new position in shares of Capricor Therapeutics in the 3rd quarter worth about $938,000. State Street Corp lifted its stake in shares of Capricor Therapeutics by 27.8% in the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock valued at $7,792,000 after purchasing an additional 111,291 shares in the last quarter. Sassicaia Capital Advisers LLC acquired a new stake in Capricor Therapeutics during the 3rd quarter worth approximately $192,000. Finally, Point72 Asset Management L.P. purchased a new position in Capricor Therapeutics in the third quarter valued at approximately $3,806,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

(Get Free Report)

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Recommended Stories